JNJ-10198409
Modify Date: 2024-01-13 14:43:47
JNJ-10198409 structure
|
Common Name | JNJ-10198409 | ||
|---|---|---|---|---|
| CAS Number | 627518-40-5 | Molecular Weight | 325.337 | |
| Density | 1.4±0.1 g/cm3 | Boiling Point | 528.8±50.0 °C at 760 mmHg | |
| Molecular Formula | C18H16FN3O2 | Melting Point | N/A | |
| MSDS | USA | Flash Point | 273.6±30.1 °C | |
Use of JNJ-10198409JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC50=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM)[1][2]. |
| Name | N-(3-fluorophenyl)-6,7-dimethoxy-1,4-dihydroindeno[1,2-c]pyrazol-3-amine |
|---|---|
| Synonym | More Synonyms |
| Description | JNJ-10198409 is a relatively selective, orally active, and ATP competitive PDGF-RTK (platelet-derived growth factor receptor tyrosine kinase) inhibitor (IC50=2 nM). It is a dual-mechanism, antiangiogenic, and tumor cell antiproliferative agent. JNJ-10198409 has good activity against PDGFR-β kinase (IC50=4.2 nM) and PDGFR-α kinase (IC50=45 nM)[1][2]. |
|---|---|
| Related Catalog | |
| Target |
PDGFRβ:4.2 nM (IC50) PDGFRα:45 nM (IC50) |
| In Vitro | JNJ-10198409 has potent antiproliferative activity in six of eight human tumor cell lines (IC50<0.033 μM) and is a potent inhibitor of the c-Abl kinase (IC50=22 nM)[1][2]. |
| References |
| Density | 1.4±0.1 g/cm3 |
|---|---|
| Boiling Point | 528.8±50.0 °C at 760 mmHg |
| Molecular Formula | C18H16FN3O2 |
| Molecular Weight | 325.337 |
| Flash Point | 273.6±30.1 °C |
| Exact Mass | 325.122650 |
| PSA | 62.40000 |
| LogP | 3.91 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.671 |
| RIDADR | NONH for all modes of transport |
|---|
|
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: platelet-derived growth factor receptor tyrosine kinase inhibitors with broad antiproliferative activity against tumor cells.
J. Med. Chem. 48 , 8163-8173, (2005) A series of (6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines has been optimized to preserve both potent kinase inhibition activity against the angiogenesis target, the receptor tyrosin... |
|
|
Validation of in vivo pharmacodynamic activity of a novel PDGF receptor tyrosine kinase inhibitor using immunohistochemistry and quantitative image analysis.
Mol. Cancer Ther. 4 , 1198-1204, (2005) With the advent of agents directed against specific molecular targets in drug discovery, it has become imperative to show a compound's cellular impact on the intended biomolecule in vivo. The objectiv... |
| Indeno[1,2-c]pyrazol-3-amine, N-(3-fluorophenyl)-2,4-dihydro-6,7-dimethoxy- |
| (6,7-dimethoxy-2,4-dihydroindeno(1,2-c)pyrazol-3-yl)(3-fluorophenyl)amine |
| N-(3-Fluorophenyl)-6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-amine |
| PDGF Receptor Tyrosine Kinase Inhibitor IV |
| 3-Fluoro-N-(6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamine |